Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007761 | 0.79 | SMN1; SMN2 (0.36) | CCNA2CDK2CCNA1 | |
| SCHEMBL18632627 | 0.73 | ERCC1 (0.31) | TMEM97SIGMAR1 | |
| SCHEMBL18655534 | 0.73 | GABRA1 (0.32) | TMEM97SIGMAR1 | |
| SCHEMBL1007963 | 0.73 | LMNA (0.33) | — | |
| SCHEMBL18665244 | 0.70 | NPSR1 (0.35) | TMEM97SIGMAR1 | |
| SCHEMBL31613039 | 0.69 | IKBKB (0.32) | TMEM97SIGMAR1 | |
| SCHEMBL17287036 | 0.69 | CCNA2 (0.50) | CCNA2CDK2CCNA1 | |
| SCHEMBL1006129 | 0.66 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL22029865 | 0.64 | TMEM97 (0.39) | TMEM97SIGMAR1 | |
| SCHEMBL20400046 | 0.64 | NLRP3 (0.39) | TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | ADORA2A 178/4885ADORA1 88/4885CCNA2 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.